论文部分内容阅读
目的探讨乳腺癌患者血清糖类抗原153(CA153)和癌胚抗原(CEA)表达及临床意义。方法利用全自动快速粒子酶免疫分析系统(IMX),检测30例健康人、52例乳腺良性疾病和208例乳腺癌患者血清CA153和CEA的水平,分析CA153和CEA检测值与乳腺癌临床特征之间的关系。结果乳腺癌患者治疗前血清CA153及CEA的水平明显高于治疗后的水平(P<0.001),初诊初治及复发转移患者的血清CA153及CEA的水平明显高于乳腺良性病变和健康人群(P<0.001);联合检测可以提高对乳腺癌诊断的阳性率。结论联合检测CA153及CEA水平可以提高对乳腺癌诊断的敏感性和准确性,并可用于该肿瘤的预后判断。
Objective To investigate the expression of serum carbohydrate antigen 153 (CA153) and carcinoembryonic antigen (CEA) in patients with breast cancer and its clinical significance. Methods Serum levels of CA153 and CEA were measured in 30 healthy individuals, 52 benign breast diseases and 208 breast cancer patients by using automated rapid particle enzyme immunoassay system (IMX). The correlation between CA153 and CEA levels and the clinical features of breast cancer Relationship between. Results The levels of serum CA153 and CEA in patients with breast cancer before treatment were significantly higher than those after treatment (P <0.001). The serum levels of CA153 and CEA in newly diagnosed and relapsed patients were significantly higher than those in benign breast diseases and healthy subjects (P <0.001); combined testing can improve the positive rate of breast cancer diagnosis. Conclusion The combined detection of CA153 and CEA levels can improve the sensitivity and accuracy of breast cancer diagnosis and can be used for the prognosis of the tumor.